{
    "organizations": [],
    "uuid": "7704f7d76744c1bd83d26146a6feb592bbdbdf31",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/05/02/globe-newswire-jounce-therapeutics-to-announce-first-quarter-2018-financial-results-and-host-conference-call-on-wednesday-may-9-2018.html",
    "ord_in_thread": 0,
    "title": "Jounce Therapeutics to Announce Results and Host Conference Call on Wednesday, May 9, 2018",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "CAMBRIDGE, Mass., May 02, 2018 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report first quarter 2018 financial results on Wednesday, May 9, 2018. Jounce Therapeutics' management team will host a live conference call and webcast to discuss these results and provide a corporate update at 8:00 a.m. ET.\nConference Call and Webcast\nTo access the conference call, please dial (866) 916-3380 (domestic) or (210) 874-7772 (international) and refer to conference ID 3760478. The live webcast can be accessed under \"Events & Presentations\" in the Investors and Media section of the company's website at www.jouncetx.com . The webcast will be archived and made available for replay on the company’s website approximately two hours after the call and will be available for 30 days thereafter.\nAbout Jounce Therapeutics\nJounce Therapeutics, Inc. is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right immunotherapy to the right patient. Jounce’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates ICOS and is currently in the Phase 2 portion of the Phase 1/2 ICONIC trial. For more information, please visit www.jouncetx.com .\nInvestor and Media Contact:\nKomal Joshi\nJounce Therapeutics, Inc.\n(857) 320-2523\nkjoshi@jouncetx.com\nSource:Jounce Therapeutics, Inc.",
    "published": "2018-05-02T16:00:00.000+03:00",
    "crawled": "2018-05-02T17:21:32.008+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "cambridge",
        "may",
        "globe",
        "newswire",
        "jounce",
        "therapeutic",
        "nasdaq",
        "jnce",
        "clinical",
        "stage",
        "company",
        "focused",
        "discovery",
        "development",
        "novel",
        "cancer",
        "immunotherapy",
        "predictive",
        "biomarkers",
        "today",
        "announced",
        "report",
        "first",
        "quarter",
        "financial",
        "result",
        "wednesday",
        "may",
        "jounce",
        "therapeutic",
        "management",
        "team",
        "host",
        "live",
        "conference",
        "call",
        "webcast",
        "discus",
        "result",
        "provide",
        "corporate",
        "update",
        "et",
        "conference",
        "call",
        "webcast",
        "access",
        "conference",
        "call",
        "please",
        "dial",
        "domestic",
        "international",
        "refer",
        "conference",
        "id",
        "live",
        "webcast",
        "accessed",
        "event",
        "presentation",
        "investor",
        "medium",
        "section",
        "company",
        "website",
        "webcast",
        "archived",
        "made",
        "available",
        "replay",
        "company",
        "website",
        "approximately",
        "two",
        "hour",
        "call",
        "available",
        "day",
        "thereafter",
        "jounce",
        "therapeutic",
        "jounce",
        "therapeutic",
        "clinical",
        "stage",
        "immunotherapy",
        "company",
        "dedicated",
        "transforming",
        "treatment",
        "cancer",
        "developing",
        "therapy",
        "enable",
        "immune",
        "system",
        "attack",
        "tumor",
        "provide",
        "benefit",
        "patient",
        "use",
        "translational",
        "science",
        "platform",
        "jounce",
        "first",
        "focus",
        "specific",
        "cell",
        "type",
        "within",
        "tumor",
        "prioritize",
        "target",
        "identifies",
        "related",
        "biomarkers",
        "designed",
        "match",
        "right",
        "immunotherapy",
        "right",
        "patient",
        "jounce",
        "lead",
        "product",
        "candidate",
        "monoclonal",
        "antibody",
        "bind",
        "activates",
        "icos",
        "currently",
        "phase",
        "portion",
        "phase",
        "iconic",
        "trial",
        "information",
        "please",
        "visit",
        "investor",
        "medium",
        "contact",
        "komal",
        "joshi",
        "jounce",
        "therapeutic",
        "kjoshi",
        "source",
        "jounce",
        "therapeutic",
        "inc"
    ]
}